ES2172179T3 - Composiciones farmaceuticas de liberacion controlada que contienen tiagabina. - Google Patents

Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.

Info

Publication number
ES2172179T3
ES2172179T3 ES98937738T ES98937738T ES2172179T3 ES 2172179 T3 ES2172179 T3 ES 2172179T3 ES 98937738 T ES98937738 T ES 98937738T ES 98937738 T ES98937738 T ES 98937738T ES 2172179 T3 ES2172179 T3 ES 2172179T3
Authority
ES
Spain
Prior art keywords
hours
controlled release
tiagabine
thiagabine
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98937738T
Other languages
English (en)
Spanish (es)
Inventor
Maurice Joseph Anthony Clancy
Michelle Caulfield
Kenneth Iain Cumming
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26320083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172179(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of ES2172179T3 publication Critical patent/ES2172179T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
ES98937738T 1997-08-01 1998-07-30 Composiciones farmaceuticas de liberacion controlada que contienen tiagabina. Expired - Lifetime ES2172179T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine

Publications (1)

Publication Number Publication Date
ES2172179T3 true ES2172179T3 (es) 2002-09-16

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98937738T Expired - Lifetime ES2172179T3 (es) 1997-08-01 1998-07-30 Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.

Country Status (10)

Country Link
EP (1) EP0991409B1 (enExample)
JP (1) JP2001511450A (enExample)
AT (1) ATE212550T1 (enExample)
AU (1) AU8643698A (enExample)
CA (1) CA2299464C (enExample)
DE (1) DE69803670T2 (enExample)
DK (1) DK0991409T3 (enExample)
ES (1) ES2172179T3 (enExample)
PT (1) PT991409E (enExample)
WO (1) WO1999006045A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
PT830132E (pt) * 1995-05-05 2002-07-31 Novo Nordisk As Composicao farmaceutica contendo hidrocloruro de tiagabina como ingrediente activo e seu processo de preparacao
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
JP2000511538A (ja) * 1996-05-24 2000-09-05 スミスクライン・ビーチャム・コーポレイション 鎮咳剤としてのｇａｂａ取り込み阻害剤の使用
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Also Published As

Publication number Publication date
ATE212550T1 (de) 2002-02-15
WO1999006045A1 (en) 1999-02-11
DK0991409T3 (da) 2002-03-25
PT991409E (pt) 2002-06-28
EP0991409B1 (en) 2002-01-30
CA2299464C (en) 2009-02-17
DE69803670D1 (de) 2002-03-14
AU8643698A (en) 1999-02-22
JP2001511450A (ja) 2001-08-14
DE69803670T2 (de) 2002-11-21
CA2299464A1 (en) 1999-02-11
EP0991409A1 (en) 2000-04-12

Similar Documents

Publication Publication Date Title
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
NO971206D0 (no) Forlenget-frigjöringsformulering
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
IL121126A0 (en) Method of increasing expression of molecular chaperon by an eukarytic cell
DK0642344T3 (da) Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
ES2172179T3 (es) Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
FI933975A0 (fi) Tabletter som kontrollerat avgiver naproxen
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
BR0014440A (pt) Formulações de liberação controlada oral
ATE194498T1 (de) Wasserfreies mittel auf lactulosebasis
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
ES2165734T3 (es) Composiciones basadas en pentoxifilina y anticitoquina.
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
MXPA02012957A (es) Formulacion nueva.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 991409

Country of ref document: ES